{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T12:25:08Z","timestamp":1775564708139,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.euo.2019.09.005","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T23:25:55Z","timestamp":1570490755000},"page":"618-627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry"],"prefix":"10.1016","volume":"4","author":[{"given":"Malou C.P.","family":"Kuppen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans M.","family":"Westgeest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonsus J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reindert J.A.","family":"van Moorselaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juleon L.L.M.","family":"Coenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.M. (Fons)","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daan","family":"ten Bokkel Huinink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Fossion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud M.","family":"Geenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathijs P.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Addy C.M.","family":"van de Luijtgaarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco B.","family":"Polee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir I.","family":"Weijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes J.","family":"van de Wouw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2019.09.005_bib0005","series-title":"Kostenprognose van Opname van Cabazitaxel (Jevtana\u00ae) in de Beleidsregel Dure Geneesmiddelen","author":"Commissie Farmaceutische Hulp","year":"2011"},{"key":"10.1016\/j.euo.2019.09.005_bib0010","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","article-title":"Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer","volume":"41","author":"Buttigliero","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"15_suppl","key":"10.1016\/j.euo.2019.09.005_bib0015","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2018.36.15_suppl.5015","article-title":"Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCRPC): results for 2nd-line therapy","volume":"36","author":"Khalaf","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.09.005_bib0020","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clgc.2017.09.008","article-title":"Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2019.09.005_bib0025","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pros.23141","article-title":"Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies","volume":"76","author":"Nadal","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2019.09.005_bib0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/iju.13346","article-title":"Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-na\u00efve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration","volume":"24","author":"Terada","year":"2017","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2019.09.005_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pros.23094","article-title":"Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation","volume":"76","author":"Badrising","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2019.09.005_bib0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.clgc.2014.10.006","article-title":"Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series","volume":"13","author":"Petrelli","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2019.09.005_bib0045","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.09.005_bib0050","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.clgc.2016.07.005","article-title":"Impact of prior use of an androgen receptor-axis-targeted (ARAT) agent with or without subsequent taxane therapy on the efficacy of another ARAT agent in patients with metastatic castration-resistant prostate cancer","volume":"15","author":"Miyake","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2019.09.005_bib0055","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.euf.2016.09.008","article-title":"Differences in trial and real-world populations in the dutch castration-resistant prostate Cancer registry","volume":"4","author":"Westgeest","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2019.09.005_bib0060","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.09.005_bib0065","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clgc.2017.11.007","article-title":"Comparison of alternative androgen receptor-axis-targeted agent (ARATA) and docetaxel as second-line therapy for patients with metastatic castration-resistant prostate cancer with progression after initial ARATA in real-world clinical practice in Japan","volume":"16","author":"Miyake","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2019.09.005_bib0070","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2019.09.005_bib0075","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot","year":"2013","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10.1016\/j.euo.2019.09.005_bib0080","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/jco.2014.32.4_suppl.18","article-title":"The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC","volume":"32","author":"Cheng","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.09.005_bib0085","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.09.005_bib0090","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.09.005_bib0095","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.09.005_bib0100","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2019.09.005_bib0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eururo.2014.10.014","article-title":"Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study","volume":"68","author":"Caffo","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.09.005_bib0110","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2019.09.005_bib0115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.clgc.2016.03.021","article-title":"The effect of time to castration resistance on outcomes with abiraterone and enzalutamide in metastatic prostate cancer","volume":"14","author":"Hung","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2019.09.005_bib0120","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/cncr.30587","article-title":"Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel","volume":"123","author":"Armstrong","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2019.09.005_bib0125","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1158\/1078-0432.CCR-14-1549","article-title":"Clinical correlation between prostate-specific antigen kinetics and overall survival in abiraterone acetate-treated castration-resistant prostate cancer patients","volume":"21","author":"Xu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2019.09.005_bib0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2017.07.035","article-title":"Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for \u226524 weeks in Europe","volume":"74","author":"de Bono","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2019.09.005_bib0135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2014.07.028","article-title":"Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis","volume":"68","author":"Brasso","year":"2015","journal-title":"Eur Urol"},{"issue":"27","key":"10.1016\/j.euo.2019.09.005_bib0140","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","article-title":"End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice","volume":"29","author":"Scher","year":"2011","journal-title":"J Clin Oncol."}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931119301464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931119301464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:46:57Z","timestamp":1762876017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931119301464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2588931119301464"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2019.09.005","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2019.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}